Apogee Therapeutics Ownership | Who Owns Apogee Therapeutics?
Apogee Therapeutics Ownership Summary
Apogee Therapeutics is owned by 11.33% institutional investors, 6.09% insiders, and 82.58% retail investors. Vr adviser is the largest institutional shareholder, holding 14.54% of APGE shares.
APGE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Apogee Therapeutics | 11.33% | 6.09% | 82.58% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 8.49M | 14.54% | $337.44M |
| Fmr | 6.92M | 11.84% | $274.79M |
| Wellington management group llp | 4.72M | 8.08% | $187.67M |
| Blackrock funding, inc. /de | 3.78M | 6.44% | $285.62M |
| Vanguard group | 2.86M | 4.86% | $215.71M |
| Rtw investments, lp | 2.71M | 4.64% | $107.75M |
| Driehaus capital management | 2.16M | 3.69% | $85.76M |
| Fairmount funds management | 2.05M | 3.51% | $81.39M |
| State street | 1.66M | 2.83% | $65.77M |
| Paradigm biocapital advisors lp | 1.52M | 2.60% | $60.46M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vr adviser | 8.49M | 18.99% | $337.44M |
| Fairmount funds management | 2.05M | 7.32% | $81.39M |
| Great point partners | 304.00K | 4.98% | $12.08M |
| Affinity asset advisors | 1.17M | 4.06% | $46.62M |
| Allostery investments lp | 6.00K | 3.32% | $260.58K |
| First turn management | 402.81K | 2.40% | $16.00M |
| Opaleye management | 363.26K | 2.04% | $14.43M |
| Ikarian capital | 232.05K | 1.94% | $10.08M |
| Paradigm biocapital advisors lp | 1.52M | 1.72% | $60.46M |
| Braidwell lp | 1.44M | 1.70% | $57.16M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | 3.78M | 0.00% | 1.10M |
| Wellington management group llp | 4.72M | 0.03% | 917.99K |
| Vanguard group | 2.86M | 0.00% | 612.19K |
| Jennison associates | 578.63K | 0.03% | 578.63K |
| Paradigm biocapital advisors lp | 1.52M | 1.72% | 563.13K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Octagon capital advisors lp | - | - | -10.70M |
| Ra capital management | - | - | -1.57M |
| Point72 asset management | - | - | -1.23M |
| Adage capital partners gp | 235.00K | 0.01% | -1.06M |
| Woodline partners lp | 57.32K | 0.01% | -812.89K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vestal point capital, lp | 425.00K | 0.76% | 425.00K | $16.89M |
| Opaleye management | 363.26K | 2.04% | 363.26K | $14.43M |
| Pictet asset management sa | 312.88K | 0.02% | 312.88K | $23.62M |
| Great point partners | 304.00K | 4.98% | 304.00K | $12.08M |
| Loomis sayles & co l p | 255.44K | 0.02% | 255.44K | $19.28M |
Sold Out
| Holder | Change |
|---|---|
| True wealth design | -1.00 |
| Montag a & associates | -4.00 |
| Principal securities | -5.00 |
| Southstate | -5.00 |
| Parallel advisors | -6.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 48 | -73.63% | 6,658,071 | -88.83% | 11 | 0.11% | 31 | -63.95% | 11 | -81.03% |
| Sep 30, 2025 | 51 | -73.85% | 4,589,108 | -92.07% | 7 | 0.08% | 23 | -75.53% | 20 | -68.75% |
| Jun 30, 2025 | 194 | 9.60% | 57,823,236 | -17.56% | 98 | 0.68% | 93 | 9.41% | 64 | 8.47% |
| Mar 31, 2025 | 178 | 11.25% | 72,188,053 | 28.01% | 124 | 1.19% | 85 | -10.53% | 59 | 55.26% |
| Dec 31, 2024 | 162 | 10.96% | 57,868,275 | 3.16% | 104 | 1.07% | 97 | 29.33% | 38 | -17.39% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 04, 2026 | Dambkowski Carl | Chief Medical Officer | Sell | $14.65K |
| Mar 04, 2026 | Dambkowski Carl | Chief Medical Officer | Sell | $226.81K |
| Mar 04, 2026 | Dambkowski Carl | Chief Medical Officer | Sell | $149.36K |
| Mar 02, 2026 | Henderson Jane | Chief Financial Officer | Sell | $20.48K |
| Mar 02, 2026 | Henderson Jane | Chief Financial Officer | Sell | $20.83K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 32 |
| 2025 Q4 | 1 | 19 |
| 2025 Q3 | - | 6 |
| 2025 Q2 | - | 5 |
| 2025 Q1 | - | 10 |
APGE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools